Masters Specialty Pharma has joined this year’s #RareDiseaseDay movement by becoming an official corporate ‘friend’. Masters’ has international offices in the UK, US, El Salvador and Brazil which will all participate in a range of local fund raising and awareness activities, the proceeds of which will be donated to fund research into rare diseases.
Rare Disease Day, which takes place on the last day of February every year, was launched by Eurordis in 2008 and is the official voice of 30 million people affected by rare diseases across Europe. Since its foundation, the initiative has spread to over 94 countries with the aim of raising awareness amongst the general public, decision-makers, researchers and pharmaceutical companies about rare diseases and their impact on patients’ lives.
Dr Zulf Masters, CEO and Founder of Masters, explains why rare disease day is important to the company:
“As a company driven by the guiding mantra of ‘medicines reaching further’ we are committed to helping patients get access to the drugs they need wherever they are in the world. Rare conditions, of which there are over 7000, have a devastating impact on patients and their carers. As many of these conditions have no existing effective cure, the problem is compounded by a lack of scientific knowledge about each disease and is impacted by inequalities in access to treatment and care. This is where an initiative like Rare Disease Day is so important – to shine a light on the plight of those affected and ensure rare diseases get the attention they deserve.”
Masters Speciality Pharma specialises in sourcing medicines from the UK, Europe and US to help address the unmet needs of patients in Latin America, Central America, the Caribbean and the Middle East. Masters was proud to be the first company to provide an orphan drug to help to treat iron overload in patients with thalassaemia, in Lebanon, via and exclusive distribution agreement Masters has several other exclusive distribution agreements for branded products, including treatments for Orphan diseases, and is continually seeking further partnerships.